GGF2 (Nrg1-β3) treatment enhances NG2+ cell response and improves functional recovery after spinal cord injury.
about
Oligodendrogenesis in the normal and pathological central nervous systemRegulating Axonal Responses to Injury: The Intersection between Signaling Pathways Involved in Axon Myelination and The Inhibition of Axon RegenerationUnderstanding the NG2 Glial Scar after Spinal Cord InjuryDifferentiation of human umbilical cord matrix mesenchymal stem cells into neural-like progenitor cells and maturation into an oligodendroglial-like lineage.NG2-glia and their functions in the central nervous system.Demyelination as a rational therapeutic target for ischemic or traumatic brain injury.TrkB.T1 contributes to neuropathic pain after spinal cord injury through regulation of cell cycle pathways.PPAR agonists as therapeutics for CNS trauma and neurological diseasesGenetic and Pharmacological Inhibition of p38α Improves Locomotor Recovery after Spinal Cord Injury.Spinal cord contusion.Species-specific effects of neuregulin-1β (cimaglermin alfa) on glucose handling in animal models and humans with heart failure.Cell transplantation therapy for spinal cord injury.Dysregulation of the neuregulin-1-ErbB network modulates endogenous oligodendrocyte differentiation and preservation after spinal cord injury.SOX2 expression is upregulated in adult spinal cord after contusion injury in both oligodendrocyte lineage and ependymal cells.Neuregulin-1: a novel regulator of glial response in spinal cord injury.Stem Cells Therapy for Spinal Cord Injury.Microenvironmental regulation of oligodendrocyte replacement and remyelination in spinal cord injury.Neuregulin improves response to glucose tolerance test in control and diabetic rats.
P2860
Q21129352-E599B95B-8E8F-4721-8ACA-567DFC88D9BAQ26745419-F55002C2-0E14-43B2-9046-FD57A5E07A3EQ28078778-0BD96F9F-4422-4B70-A997-E3E4A8B20BCFQ34428273-83F4CC1B-9E57-4621-A3BD-4FEDC07598F9Q35751998-7E59D732-7511-40FF-A6F3-DA70F05788C2Q36090107-68DDC651-5413-4B4F-B639-5862DBA4293CQ37041596-C13EAF1B-16EC-4643-8A11-6A39ABC18C3CQ37400355-CCADD847-D9F1-4172-8AAB-519DD93361DCQ37647554-617DFE70-921C-4F72-B54F-3B12398B052EQ38248010-898321B5-404C-410A-9C2A-7BC428BEB3F9Q38638832-27095B91-28FF-4328-B119-E881F6B9F15BQ39261219-3F0EE67B-7D6B-4F61-B1F9-75EFA47D34B3Q45139454-563AADD1-F4D0-46A6-8770-004334EDFECFQ45354213-D99CA0FA-F0CF-4D18-9485-A9731A675285Q46250882-B6E8BE6F-3C48-48EE-A9C3-913AABEA0F57Q52619084-17ED8A7E-CA2E-41DE-B6A3-E5C85582FDF8Q53180449-2FE33EB7-32AC-459B-9C17-920A1B063307Q54225414-C2947A0C-6B82-4877-B72C-D681A8403030
P2860
GGF2 (Nrg1-β3) treatment enhances NG2+ cell response and improves functional recovery after spinal cord injury.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
GGF2 (Nrg1-β3) treatment enhan ...... very after spinal cord injury.
@en
GGF2
@nl
type
label
GGF2 (Nrg1-β3) treatment enhan ...... very after spinal cord injury.
@en
GGF2
@nl
prefLabel
GGF2 (Nrg1-β3) treatment enhan ...... very after spinal cord injury.
@en
GGF2
@nl
P2093
P2860
P356
P1433
P1476
GGF2 (Nrg1-β3) treatment enhan ...... overy after spinal cord injury
@en
P2093
April Sharp
Jean R Wrathall
Junfang Wu
Laila J Zai
Matthew T Whittaker
Ransom Wyse
P2860
P304
P356
10.1002/GLIA.21262
P577
2011-10-31T00:00:00Z